MedTrace Logo

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

NCT06745063 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-14

No results posted yet for this study

Summary

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Conditions

Interventions

DRUG

Empagliflozin

12 week treatment with 10mg empagliflozin daily

DRUG

Placebo

12 week treatment with 10mg placebo daily

Sponsors & Collaborators

  • University of Missouri-Columbia

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Jaume Padilla Parellada, PhD · Harry S. Truman Memorial, Columbia, MO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-30
Primary Completion
2028-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745063 on ClinicalTrials.gov